Desloratadine for allergic rhinitis

Wilken, Jeffrey; Daly, Adrian; Sullivan, Cynthia; Kim, Harold

doi:10.1586/1744666x.2.2.209

Cited by 9 publications

(4 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since its launch, a sizeable number of placebo‐controlled trials demonstrating the efficacy of desloratadine in AR have been reported. Results also suggest that desloratadine is associated with symptomatic and particularly objective improvements (e.g., nasal airflow) in nasal congestion (11). It has been argued that such effects on nasal congestion may be due to systemic effects of desloratadine on mediators of allergic inflammation (12).…”

mentioning

confidence: 95%

Review article: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta‐analysis of randomized, double‐blind, controlled trials

Canonica

Tarantini

Compalati

et al. 2007

Allergy

View full text Add to dashboard Cite

The objective of the study is to assess the efficacy of the nonsedating antihistamine, desloratadine, in the treatment of allergic rhinitis (AR). A search of MEDLINE, EMBASE, LILACS, and CINAHL databases was undertaken from January, 1966 to May, 2006. Double‐blind, randomized, controlled studies of desloratadine in the treatment of AR in adult patients were carried out. The measured outcomes included the total symptoms score, the total nasal symptoms score, nasal airflow, and inflammatory markers (nasal eosinophils, nasal interleukin‐4). The analysis included the calculation of standardized mean difference (SMD). A total of 57 studies were analyzed, and 13 randomized, double‐blind, controlled trials were included in the meta‐analysis. The trials included 3108 subjects who had completed studies involving desloratadine. There was significant heterogeneity among the study results, because of differing study methodologies. Desloratadine was associated with significant reductions in total symptoms scores (SMD −1.63; 95% CI −2.75 to −0.51; P = 0.004) and total nasal symptoms score (SMD −0.66; 95% CI −0.91 to −0.42; P < 0.001), when compared with placebo. Analysis of objective data on nasal blockage demonstrated a significant improvement in nasal airflow with desloratadine, when compared with placebo (SMD 0.32; 95% CI 0.10 to 0.55; P = 0.005). A benefit favoring desloratadine over placebo in terms of nasal eosinophil levels was also noted in the analysis. This meta‐analysis confirms the reduction of AR symptoms and improvement in nasal airflow seen in individual studies of desloratadine. Objective improvements in nasal airflow, total symptoms, and total nasal symptoms seen with desloratadine are supported by Ia evidence.

show abstract

mentioning

confidence: 95%

Review article: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta‐analysis of randomized, double‐blind, controlled trials

Canonica

Tarantini

Compalati

et al. 2007

Allergy

View full text Add to dashboard Cite

show abstract

“…6 Desloratadin merupakan metabolit aktif utama dari loratadin yang dapat mengurangi gejala hidung maupun bukan gejala hidung pada penderita RA, maupun urtikaria idiopatik kronik. 7,8 Penelitian invitro lain juga menunjukkan afinitas desloratadin terhadap reseptor H1 adalah 50-194 kali lipat lebih besar dibanding loratadin, cetirizine maupun feksofenadin. 9 Salah satu sitokin dari Th2 yang berperan penting dalam patofisiologi RA adalah IL-4.…”

Section: Penelitianunclassified

“…Data dari penelitian preklinis, desloratadin 60 kali lebih selektif terhadap reseptor H1 dibanding reseptor H2, serta tidak memiliki afinitas terhadap reseptor dopamin, monoamine oxidase, acetylcholinesterase, δ-amino butyric acid atau reseptor bradikinin. 8,16 Penelitian preklinis afinitas desloratadin terhadap reseptor H1, 50-194 kali lipat lebih besar dibanding loratadin, cetirizine maupun feksofenadin. 17,18 Pada penelitian QingJia et al 19 dari Januari sampai Oktober 2014 pada penderita RA di Cina diberikan terapi desloratadin dan loratadin, memperlihatkan desloratadin memiliki efek terapi terhadap gejala hidung pilek, hidung tersumbat, gatal hidung, bersin, dan edem konka inferior lebih baik dibandingkan dengan loratadin.…”

Section: Diskusiunclassified

Efektivitas desloratadin terhadap skor gejala hidung total dan kadar interleukin-4 sekret hidung rinitis alergi

Purwaningsih¹,

Pawarti²,

Surarso³

2018

Oto Rhino Laryn Indones

View full text Add to dashboard Cite

Latar belakang: Rinitis alergi (RA) adalah penyakit atopi yang umum terjadi, namun terapi yangtersedia mempunyai keterbatasan baik dalam penggunaan maupun angka keberhasilan. Desloratadinberperan sebagai terapi alternatif RA yang dapat menghilangkan keseluruhan gejala RA dan menurunkankadar interleukin-4 (IL-4) sekret hidung. Tujuan: Menganalisis efektivitas desloratadin dibandingkandengan loratadin dalam menurunkan skor gejala hidung total dan IL-4 sekret hidung pada penderita RA.Metode: Merupakan double blind randomised clinical trial with pre-post test design. Analisis data denganindependent sample t-test. Sebanyak 24 penderita RA dibagi menjadi 2 kelompok terapi yaitu kelompokstudi (desloratadin), dan kelompok kontrol (loratadin). Evaluasi berdasarkan skor gejala hidung total danIL-4 sekret hidung, pra dan pasca 15 hari terapi. Hasil: Penelitian yang dilakukan sejak bulan Juli sampaiOktober 2016 menunjukkan hasil berupa perbedaan bermakna rerata persentase penurunan skor gejalahidung total kelompok desloratadin dibandingkan kelompok loratadin (p=0,000). Perbandingan penurunankadar IL-4 sekret hidung antara kelompok desloratadin dengan loratadin adalah berbeda tidak bermakna(p=0,236). Kesimpulan: Penurunan skor gejala hidung total desloratadin lebih besar dibandingkan denganloratadin, dan tidak didapatkan perbedaan penurunan pada kadar IL-4 sekret hidung. ABSTRACTBackground: Allergic rhinitis (AR) is a common atopic disease but its current treatment is limitedboth in usage, as well as in the success rate. Desloratadine is an alternative choice in the treatment ofAR, and it could reduce the Interleukin (IL-4) nasal secretion level. Purpose: To assess the effectivenessof desloratadine compared to loratadine in decreasing total nasal symptom score (TNSS) and levels ofIL-4 nasal secretions in AR patients. Method: A double blind randomized clinical trial (RCT). Twentyfour AR patients were divided into two treatment groups: study group (desloratadin) and control group(loratadine). Evaluation was based on TNSS and IL-4 nasal secretion level pre and post 15 days oftreatment. Result: Conducted from July to October 2016, this study showed the mean of TNSS reductionpercentage between desloratadine group compared to loratadine group was significant (p=0.000).The comparison of reduction of IL-4 nasal secretion level between desloratadine group and loratadinegroup was not significantly different (p=0.236). Conclusion: The TNSS decreased more in desloratadinecompared to loratadine, but there was no significant difference between both groups in the levels of IL-4nasal secretions

show abstract

“…The latest research proved that desloratadine was an active metabolite from loratadine and as a single therapy to eliminate AR symptoms especially stuffy nose and reduce IL-4 level in nasal secretions 4 . Desloratadine is the main active metabolite from loratadine that can decrease either nose symptoms or other symptoms such as chronic idiopathic urticaria 5 . Another in vitro research also showed that the affinity of desloratadine towards H1 receptor was 50-194 times bigger than loratadine, cetirizine, and fexofenadine 6 .…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness Comparison of Desloratadine and Loratadine in Reducing Total Nasal Symptom Score and the Level of Interleukin 4 in the Nasal Secretions of Allergic Rhinitis Patients

2020

IJFMT

View full text Add to dashboard Cite

Background: Allergic rhinitis (AR) is a common atopic disease; however, the available therapy has limitation in the usage and its success rate. Desloratadine has a role as an alternative allergic rhinitis therapy to eliminate the overall symptoms of AR and reduce IL-4 level in nasal secretions.Method: This study was double-blind randomised clinical trial with pre-post test design. The data was analyzed by using independent sample t-test. There were 24 AR patients divided into 2 therapy groups which were study group (desloratadine) and control group (loratadine). The evaluation based on SGHT and IL-4 in nasal secretions was conducted pre and post 15 days of therapy.Results: The present study that was conducted on July-October 2016 showed significant difference in the average percentage of reduced TNSS in desloratadine group compared to loratadine group (p=0.000). The comparison of reduced level of IL-4 in nasal secretions between desloratadine and loratadine group was indicated insignificantly different. Conclusion:Reduced TNSS in desloratadine group was higher than in loratadine group. Also, there was no difference in decreased level of IL-4 in nasal secretions.

show abstract

Desloratadine for allergic rhinitis

Cited by 9 publications

References 60 publications

Review article: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta‐analysis of randomized, double‐blind, controlled trials

Review article: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta‐analysis of randomized, double‐blind, controlled trials

Efektivitas desloratadin terhadap skor gejala hidung total dan kadar interleukin-4 sekret hidung rinitis alergi

The Effectiveness Comparison of Desloratadine and Loratadine in Reducing Total Nasal Symptom Score and the Level of Interleukin 4 in the Nasal Secretions of Allergic Rhinitis Patients

Contact Info

Product

Resources

About